Compound: 4-aminopyridine
SMILES: n1ccc(N)cc1
InChIKey: NUKYPUAOHBNCPY-UHFFFAOYSA-N
Synonyms: 4-aminopyridine, 504-24-5, pyridin-4-amine, 4-Pyridinamine, Fampridine, Dalfampridine, 4-Pyridylamine, Avitrol, p-Aminopyridine, Ampyra, gamma-Aminopyridine, Amino-4 pyridine, Avitrol 200, FAMPYRA, Phillips 1861, Neurelan, 4 Aminopyridine, Fampridine-SR, fampridina, VMI 10-3, EL-970, Mi-W-3, fampridinum, NSC-15041, DTXSID0023870, VMI 103, BH3B64OKL9, 1,4-dihydropyridin-4-imine, N07XX07, Fampridine (4-aminopyridine), DTXCID003870, CHEBI:34385, 5-22-09-00106 (Beilstein Handbook Reference), NSC15041, Pymadine, Fampridine SR, VMI103, 4 Aminopyridine Sustained Release, Sustained Release, 4-Aminopyridine, Ampyra Extended Release, RefChem:54927, 207-987-9, 4-AP, Pyridine, 4-amino-, Pimadin (free base), Compound 1861, Amaya, Prc 1237, pyridin-4-ylamine, MFCD00006439, NSC 15041, Fampridine [INN], .gamma.-Aminopyridine, Dalfampridine [USAN], MLS000069400, CHEMBL284348, Dalfampridine (USAN), NCGC00015009-08, SMR000058211, ACETYL-2-13C CHLORIDE,2,2-DICHLORO- (9CI), Caswell No. 038, VMI-103, 4-amino pyridine, 4-amino-pyridine, 4- Aminopyridine, CAS-504-24-5, Ampyra (TN), HSDB 6037, SR-01000075299, EINECS 207-987-9, RCRA waste no. P008, UNII-BH3B64OKL9, EPA Pesticide Chemical Code 069201, Dalfampridine [USAN:INN], BRN 0105782, Frampridine, Ampydin, BIIB041, Pymadin, AI3-52547, BIIB 041, Fampridine-PR, Dalfampridine (4-aminopyridine), Dalfampridine-ER, 4-pyridyl amine, para-aminopyridine, pyridine-4-amine, 3rxf, Neurelan (TN), pyridine-4-ylamine, 4AP, VMI-10-3, Fampyra (TN), pyridin-4-yl-amine, 4-Aminopyridine 10, Philips 1861, 4-AMINOPYRDINE, Spectrum_000155, Tocris-0940, Fampridine (JAN/INN), 4-Aminopyridine, 98%, FAMPRIDINE [JAN], PYRIDINE,4-AMINO, Opera_ID_1768, Spectrum2_001413, Spectrum3_000914, Spectrum4_001013, Spectrum5_001501, Lopac-A-0152, DALFAMPRIDINE [II], DALFAMPRIDINE [MI], FAMPRIDINE [VANDF], UPCMLD-DP125, WLN: T6NJ DZ, 4-Aminopyridine (4-AP), FAMPRIDINE [MART.], 4-Aminopyridine, >=99%, DALFAMPRIDINE [HSDB], FAMPRIDINE [WHO-DD], Lopac0_000032, SCHEMBL53483, BSPBio_001562, DALFAMPRIDINE [VANDF], KBioGR_000282, KBioGR_001505, KBioSS_000282, KBioSS_000635, 29212-32-6, DivK1c_000572, FAMPRIDINE [EMA EPAR], SCHEMBL245056, SCHEMBL291100, SCHEMBL332270, SCHEMBL332451, SPECTRUM1501130, SPBio_001486, DALFAMPRIDINE [USP-RS], 4 AP, BIIB-041, GTPL2416, orb2893743, orb3026006, Pyridin-4-Amine; Dalfampridine, SCHEMBL1397445, SCHEMBL1683855, SCHEMBL3865305, CL-COB-III-274-1, UPCMLD-DP125:001, BDBM10458, HMS501M14, KBio1_000572, KBio2_000282, KBio2_000635, KBio2_002850, KBio2_003203, KBio2_005418, KBio2_005771, KBio3_000563, KBio3_000564, KBio3_001888, NINDS_000572, Bio1_000353, Bio1_000842, Bio1_001331, Bio2_000282, Bio2_000762, HMS1361O04, HMS1791O04, HMS1921H15, HMS1989O04, HMS2092F05, HMS2234N24, HMS3260G05, HMS3267E21, HMS3370J03, HMS3402O04, HMS3414H15, HMS3678H13, HMS3886I09, KUC111877N, Pharmakon1600-01501130, DALFAMPRIDINE [ORANGE BOOK], HY-B0604, Tox21_110065, Tox21_200793, Tox21_500032, CCG-39031, DALFAMPRIDINE [USP MONOGRAPH], EBC-03934, HB1073, NSC757845, RB8003, s5028, SBB004393, STK298717, AKOS000119896, Tox21_110065_1, BS-3729, DB06637, FA00151, LP00032, MSK000551-100M, NSC-757845, SDCCGMLS-0066228.P001, SDCCGSBI-0050021.P004, IDI1_000572, IDI1_034032, p-Aminopyridine [UN2671]  [Poison], MSK000551-1000M, NCGC00015009-01, NCGC00015009-02, NCGC00015009-03, NCGC00015009-04, NCGC00015009-05, NCGC00015009-06, NCGC00015009-07, NCGC00015009-09, NCGC00015009-10, NCGC00015009-11, NCGC00015009-12, NCGC00015009-13, NCGC00015009-14, NCGC00015009-16, NCGC00015009-23, NCGC00015009-24, NCGC00024890-01, NCGC00024890-02, NCGC00024890-03, NCGC00024890-04, NCGC00024890-05, NCGC00024890-06, NCGC00024890-07, NCGC00024890-08, NCGC00024890-09, NCGC00024890-10, NCGC00258347-01, NCGC00260717-01, BP-21343, SBI-0050021.P003, DB-028705, A0414, EU-0100032, NS00002207, ST45053817, EN300-21310, FAMPRIDINE (4-AMINOPYRIDINE) [VANDF], A 0152, D04127, 4-Aminopyridine Solution in Methanol, 100ug/mL, AB00052209_12, [J.Pharmacol.Exp.Ther. 275:864 (1995)], 4-Aminopyridine Solution in Methanol, 1000ug/mL, AC-907/25014071, F047207, Q372539, 4-Aminopyridine, PESTANAL(R), analytical standard, SR-01000075299-1, SR-01000075299-3, SR-01000075299-5, BRD-K22482860-001-20-6, BRD-K22482860-001-21-4, F2190-0487, Z104495272, Dalfampridine, United States Pharmacopeia (USP) Reference Standard, InChI=1/C5H6N2/c6-5-1-3-7-4-2-5/h1-4H,(H2,6,7
Theoretical properties:
molecular_formula: C5H6N2
molecular_weight: 94.11 g/mol
exact_mass: 94.053098200 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 1
hydrogen_bond_acceptor_count: 2
rotatable_bond_count: 0
heavy_atom_count: 7
topological_polar_surface_area: 38.9 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
physical_state: White crystals
color: White crystals
odor: Odorless
boiling_point: 524.3 °F at 760 mmHg (EPA, 1998)
melting_point: 318 °F (EPA, 1998)
density: 1.2607 at 77.54 °F (USCG, 1999) - Denser than water; will sink
flash_point: 328 °F (USCG, 1999)
vapor_pressure: 0.00034 [mmHg]
Descriptions:
pubchem: 4-aminopyridine is an aromatic amine that is pyridine bearing a single amino substituent at position 4. An orphan drug in the US, it is used to improve walking in adults with multiple sclerosis. It has a role as an avicide, a potassium channel blocker and an orphan drug. It is an aromatic amine and an aminopyridine.
chebi: An aromatic amine that is pyridine bearing a single amino substituent at position 4. An orphan drug in the US, it is used to improve walking in adults with multiple sclerosis.
chembl: DALFAMPRIDINE is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: 4-Aminopyridine (4-AP) is an organic compound with the chemical formula H2NC5H4N.  It is one of the three isomeric aminopyridines.  It is used as a research tool in characterizing subtypes of the potassium channel.  It has also been used as a drug, to manage some of the symptoms of multiple sclerosis, and is indicated for symptomatic improvement of walking in adults with several variations of the disease. It was undergoing Phase III clinical trials as of 2008, and the U.S. Food and Drug Administration (FDA) approved the compound on January 22, 2010. 4-AP has been used as treatment for KCNA2-related disorders with gene mutations that show a clear gain-of-function. Benefits include decreased seizures and improved ataxia, alertness, and cognition. Fampridine is also marketed as Ampyra (pronounced "am-PEER-ah", according to the maker's website) in the United States by Acorda Therapeutics and as Fampyra in the European Union, Canada, and Australia. In Canada, the medication has been approved for use by Health Canada since February 10, 2012.